Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
Department of Medicine, University of California-San Diego, La Jolla, California, USA.
Clin Infect Dis. 2021 Nov 2;73(9):1717-1721. doi: 10.1093/cid/ciab494.
As of March 2021, coronavirus disease 2019 (COVID-19) had caused more than 123 million infections and almost 3 million deaths worldwide. Dramatic advances have been made in vaccine development and nonpharmaceutical interventions to stop the spread of infection. However, treatments to stop disease progression are limited. A wide variety of "repurposed" drugs evaluated for treatment of COVID-19 have had little or no benefit. More recently, intravenous monoclonal antibody (mAb) combinations have been authorized by the US Food and Drug Administration for emergency use for outpatients with mild to moderate COVID-19 including some active against emerging severe acute respiratory syndrome coronavirus 2 variants of concern. Easier to administer therapeutics including intramuscular and subcutaneous mAbs and oral antivirals are in clinical trials. Reliable, safe, effective COVID-19 treatment for early infection in the outpatient setting is of urgent and critical importance. Availability of such treatment should lead to reduced progression of COVID-19.
截至 2021 年 3 月，2019 年冠状病毒病（COVID-19）在全球已导致超过 1.23 亿例感染和近 300 万人死亡。在疫苗开发和非药物干预措施方面取得了显著进展，以阻止感染的传播。然而，用于阻止疾病进展的治疗方法有限。评估用于治疗 COVID-19 的各种“再利用”药物几乎没有或没有益处。最近，美国食品和药物管理局批准静脉内单克隆抗体（mAb）联合用药用于门诊轻度至中度 COVID-19 患者的紧急使用，包括一些针对新兴严重急性呼吸综合征冠状病毒 2 关切变异株的药物。更易于管理的治疗方法，包括肌肉内和皮下 mAb 以及口服抗病毒药物，正在临床试验中。在门诊环境中对早期感染进行可靠、安全、有效的 COVID-19 治疗具有紧迫和至关重要的意义。此类治疗方法的提供应可减少 COVID-19 的进展。
